These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27324191)

  • 21. Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients.
    Ruiz J; Ramirez P; Company MJ; Gordon M; Villarreal E; Concha P; Aroca M; Frasquet J; Remedios-Marqués M; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Mar; 12():90-95. PubMed ID: 29017888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amikacin population pharmacokinetics among paediatric burn patients.
    Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
    Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of amikacin in patients with haematological malignancies.
    Romano S; Fdez de Gatta MM; Calvo MV; Caballero D; Dominguez-Gil A; Lanao JM
    J Antimicrob Chemother; 1999 Aug; 44(2):235-42. PubMed ID: 10473231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses.
    Illamola SM; Sherwin CM; van Hasselt JGC
    Clin Pharmacokinet; 2018 Oct; 57(10):1217-1228. PubMed ID: 29572662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring study.
    Telles JP; Diegues MS; Migotto KC; de Souza Borges O; Reghini R; Gavazza BV; Pinto L; Caruso P; E Silva ILF; Schmidt S; de Lima Moreira F
    Eur J Clin Pharmacol; 2023 Jul; 79(7):1003-1012. PubMed ID: 37256410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
    Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
    Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
    Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
    Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation.
    Bleyzac N; Varnier V; Labaune JM; Corvaisier S; Maire P; Jelliffe RW; Putet G; Aulagner G
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):499-504. PubMed ID: 11699615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
    Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
    Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates.
    Matcha S; Dillibatcha J; Raju AP; Chaudhari BB; Moorkoth S; Lewis LE; Mallayasamy S
    Paediatr Drugs; 2023 May; 25(3):365-375. PubMed ID: 36943583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interindividual pharmacokinetic variability in long-term antibiotherapy].
    Bourguignon L; Goutelle S; de Saint Martin JB; Guillermet A; Bouniot P; Maire P; Ducher M
    Med Mal Infect; 2010 Jan; 40(1):38-41. PubMed ID: 19346086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limited sampling strategy for estimation of amikacin optimal sampling time in critically ill adults.
    Mahmoudi L; Mohammadpour AH; Niknam R; Ahmadi A; Mojtahedzdeh M
    Anaesth Intensive Care; 2014 Mar; 42(2):228-33. PubMed ID: 24580389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.
    Illamola SM; Huynh HQ; Liu X; Bhakta ZN; Sherwin CM; Liou TG; Carveth H; Young DC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of Amikacin in Critical Care Patients on Extracorporeal Device.
    Ruiz-Ramos J; Gimeno R; Pérez F; Ramirez P; Villarreal E; Gordon M; Vicent C; Remedios Marqués M; Castellanos-Ortega Á
    ASAIO J; 2018; 64(5):686-688. PubMed ID: 29045281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis.
    Marsot A; Guilhaumou R; Azulay JP; Blin O
    J Pharm Pharm Sci; 2017; 20(0):226-238. PubMed ID: 28719359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of renal function equations to predict amikacin clearance.
    Sáez Fernández EM; Pérez-Blanco JS; Lanao JM; Calvo MV; Martín-Suárez A
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):805-813. PubMed ID: 31242039
    [No Abstract]   [Full Text] [Related]  

  • 39. Population pharmacokinetics of amikacin in a Korean clinical population.
    Jang SB; Lee YJ; Park MS; Song YG; Kim JH; Kim HK; Ahn BS; Park K
    Int J Clin Pharmacol Ther; 2011 Jun; 49(6):371-81. PubMed ID: 21612744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis.
    Lugo-Goytia G; Castañeda-Hernández G
    Ann Pharmacother; 2000 Dec; 34(12):1389-94. PubMed ID: 11144694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.